Point-of-care doesn't end in clinic.
An early-stage concept for extending clean, scheduled care habits into the hours and days after a patient leaves the chair, using a sealed, wearable dispensing platform.
This page describes an early concept WearSpray is exploring with clinical and aesthetic-practice partners. It is not a description of a cleared medical device, and WearSpray makes no claim of proven clinical efficacy for any procedure listed here.
The Problem
The outpatient black hole.
Clinical outcomes in aesthetics are shaped as much by what happens after the appointment as during it, and most of that period happens where no one from the practice can see it.
Contamination Risk
Unwashed hand contact
A compromised skin barrier, the kind left by microneedling, ablative laser resurfacing or a deep chemical peel, is a direct vector for infection and contact dermatitis the moment it is touched with unwashed hands. That is exactly how most at-home topicals get applied.
Barrier Dry-Out
The 6 to 8 hour gap
Bulky at-home products get skipped during a workday, leaving hours without the hydration compromised skin needs to stay in a moist, healing state, a gap aesthetic literature commonly associates with a higher risk of crusting and post-inflammatory pigmentation.
Compliance Decay
Reapplication every 90 to 120 minutes
Patients are typically asked to reapply on a strict schedule once they leave the chair. Aesthetic-practice literature commonly cites low adherence to that schedule, with disappointing results often attributed to the procedure rather than the missed doses.
hour hydration gap commonly reported during a typical at-home workday
the typical reapplication interval patients are asked to keep, and often don't
Figures above reflect patterns commonly cited in aesthetic-practice literature, not a WearSpray-run clinical study.
The Approach
Clean-touch ambient delivery.
The concept: a clean-touch, wearable, micro-metered delivery system designed to dispense a sealed formulation in precise doses directly onto healing tissue on a schedule, aimed at minimizing air exposure and finger contact.
For clinical and post-procedure use, the same reservoir mechanism that makes WearSpray refillable for everyday wear can also ship the opposite way: as a factory-sealed, single-formulation cartridge with no refill access at all, a tamper-evident pod that snaps into the silicone band and is swapped as a whole unit instead of being opened by hand. The reservoir was engineered from day one to be removable, which is what makes both versions possible from the same hardware platform.
Procedural Fit
Clinical indications matrix.
How the concept maps against common aesthetic and dermatology procedures, shown for discussion purposes. This is not a demonstrated or validated indication for any procedure.
Practice Economics
Keeping refills with the practice.
Many practices lose a meaningful share of post-procedure topical reorders to third-party retailers once a patient leaves the building. The concept calls for an automated low-reservoir prompt that routes a refill back to the prescribing practice rather than a general marketplace, which could help with both patient retention and recapturing revenue otherwise lost to attrition.
These are planning assumptions for discussion with practices, not measured outcomes from a deployed program.
Built on Issued Patents
Not a concept from scratch.
This explores a new application of hardware that already exists. U.S. Patent No. 12,285,084 B1, Claim 13, covers the sensing and micro-fluidic dispensing architecture behind it, and the physical platform, Safe Band Pro , is already in production with a refillable reservoir, breathing valve and adjustable band. Extending it into a closed clinical cartridge is primarily a packaging and sourcing question on top of existing hardware, though any clinical use would still require its own regulatory and clinical review, as noted below.
WearSpray is not a cleared medical device, and nothing on this page should be read as a clinical claim, a treatment recommendation, or a promise of outcomes for any procedure. Statistics referenced reflect commonly cited industry patterns, not WearSpray-run studies. Clinical deployment of the ideas described here would require appropriate regulatory review, professional clinical oversight, and formal evaluation before use with patients. This page exists to start a conversation with clinical and aesthetic-practice partners, not to describe a finished or approved product.